View ValuationLabiana Health 향후 성장Future 기준 점검 5/6Labiana Health (는) 각각 연간 54.6% 및 8.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 39.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 46.4% 로 예상됩니다.핵심 정보54.6%이익 성장률39.34%EPS 성장률Pharmaceuticals 이익 성장20.3%매출 성장률8.1%향후 자기자본이익률46.43%애널리스트 커버리지Low마지막 업데이트23 Apr 2026최근 향후 성장 업데이트Breakeven Date Change • Nov 19Forecast breakeven date moved forward to 2024The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updatesNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m).Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years.공시 • Apr 18Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026New Risk • Apr 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m).Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years.New Risk • Feb 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€31.9m market cap, or US$37.9m).분석 기사 • Nov 27These 4 Measures Indicate That Labiana Health (BME:LAB) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...공시 • Oct 29Labiana Health, S.A. to Report Q2, 2025 Results on Oct 30, 2025Labiana Health, S.A. announced that they will report Q2, 2025 results on Oct 30, 2025New Risk • Sep 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (6.0% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€31.0m market cap, or US$36.1m).New Risk • Jul 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.8% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€23.5m market cap, or US$27.6m).공시 • May 27Labiana Health, S.A., Annual General Meeting, Jun 26, 2025Labiana Health, S.A., Annual General Meeting, Jun 26, 2025. Location: av europa 34d, pozuelo de alarcon, madrid Spain공시 • Apr 13Labiana Health, S.A. to Report Fiscal Year 2024 Results on Apr 22, 2025Labiana Health, S.A. announced that they will report fiscal year 2024 results on Apr 22, 2025Breakeven Date Change • Nov 19Forecast breakeven date moved forward to 2024The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule.분석 기사 • Nov 18Labiana Health (BME:LAB) Has No Shortage Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Jun 08Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€16.0m market cap, or US$17.3m).New Risk • Sep 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (€9.24m market cap, or US$9.78m).이익 및 매출 성장 예측BME:LAB - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202893N/AN/AN/A112/31/2027908416212/31/2026827213212/31/202574401026/30/202572103N/A3/31/202570125N/A12/31/202467047N/A9/30/202467003N/A6/30/202466-1-4-2N/A3/31/202463-3-4-2N/A12/31/202360-4-4-2N/A9/30/202360-704N/A6/30/202360-1049N/A3/31/202360-927N/A12/31/202261-9-15N/A12/31/202159-2-14N/A12/31/2020601-34N/A12/31/2019511-6-1N/A12/31/2018451N/A1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: LAB 의 연간 예상 수익 증가율(54.6%)이 saving rate(2.7%)보다 높습니다.수익 vs 시장: LAB 의 연간 수익(54.6%)이 Spanish 시장(11.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: LAB 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: LAB 의 수익(연간 8.1%)이 Spanish 시장(연간 6.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: LAB 의 수익(연간 8.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: LAB의 자본 수익률은 3년 후 46.4%로 매우 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 03:11종가2026/05/22 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Labiana Health, S.A.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Iñigo Recio PascualGVC Gaesco ValoresAlfredo Echevarria OteguiLighthouse-IEAF Servicios de AnalisisLuis Esteban ArribasLighthouse-IEAF Servicios de Analisis
Breakeven Date Change • Nov 19Forecast breakeven date moved forward to 2024The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule.
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m).
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years.
공시 • Apr 18Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026
New Risk • Apr 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m).
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years.
New Risk • Feb 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€31.9m market cap, or US$37.9m).
분석 기사 • Nov 27These 4 Measures Indicate That Labiana Health (BME:LAB) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
공시 • Oct 29Labiana Health, S.A. to Report Q2, 2025 Results on Oct 30, 2025Labiana Health, S.A. announced that they will report Q2, 2025 results on Oct 30, 2025
New Risk • Sep 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (6.0% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€31.0m market cap, or US$36.1m).
New Risk • Jul 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.8% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€23.5m market cap, or US$27.6m).
공시 • May 27Labiana Health, S.A., Annual General Meeting, Jun 26, 2025Labiana Health, S.A., Annual General Meeting, Jun 26, 2025. Location: av europa 34d, pozuelo de alarcon, madrid Spain
공시 • Apr 13Labiana Health, S.A. to Report Fiscal Year 2024 Results on Apr 22, 2025Labiana Health, S.A. announced that they will report fiscal year 2024 results on Apr 22, 2025
Breakeven Date Change • Nov 19Forecast breakeven date moved forward to 2024The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule.
분석 기사 • Nov 18Labiana Health (BME:LAB) Has No Shortage Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
분석 기사 • Jun 08Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€16.0m market cap, or US$17.3m).
New Risk • Sep 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (€9.24m market cap, or US$9.78m).